A Phase 4, Observational, Multicenter, 10-year Prospective Cohort Safety Study Comparing Subjects With HIV-associated Abdominal Lipohypertrophy Exposed to EGRIFTA (Tesamorelin for Injection) to a Similar Group of Subjects Not Exposed to EGRIFTA
Phase of Trial: Phase IV
Latest Information Update: 16 Aug 2016
At a glance
- Drugs Tesamorelin (Primary)
- Indications Lipohypertrophy
- Focus Adverse reactions
- Sponsors Theratechnologies
- 02 May 2016 Planned End Date changed from 1 Jan 2025 to 1 Mar 2030.
- 02 May 2016 Planned primary completion date changed from 1 Dec 2024 to 1 Dec 2029.
- 26 Feb 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.